Vernakalant hydrochloride for the treatment of atrial fibrillation

Expert Opinion on Investigational Drugs
Dariusz KozlowskiMaciej Banach

Abstract

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Rhythm control strategy for AF is limited by drug toxicity and side effects, and recent trials have shown that this strategy is not superior to a rate control one. New antiarrhythmic drugs, free of undesired effects, would enhance rhythm control, with the possibility of sinus rhythm restoration and maintenance. A promising find in the search for new antiarrhythmic therapies is atrial-tissue specific ion channels. The findings that the ultrarapid delayed rectifier (I(Kur)) and the inwardly rectifying, acetylcholine-regulated current (I(K-Ach)) exist in atrial but not ventricular tissue increase the probability that atrioselective drugs without ventricular proarrhythmic toxicity can be developed for treatment of patients with AF. There are also other potential targets for atrial-selective therapy: transient outward current (I(to)), rapidly and slowly activating delayed rectifier currents (I(Kr) and I(Ks)), atrial sodium current (I(Na)) and atrially expressed connexins. New drugs under development with promising atrial-selectivity include: tertiapin, NIP-142, NIP-141, JTV-519, AVE0118, AVE1231, DPO-1, AZD7009 and many others. Among such new ag...Continue Reading

References

Mar 21, 1998·Journal of the American College of Cardiology·P G DaniasW J Manning
Mar 18, 1999·The American Journal of Cardiology·J T Dell'OrfanoG V Naccarelli
Dec 6, 2002·The New England Journal of Medicine·D G WyseUNKNOWN Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
Dec 6, 2002·The New England Journal of Medicine·Isabelle C Van GelderUNKNOWN Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group
Oct 22, 2003·Epidemiology·Jens FribergGorm B Jensen
Feb 3, 2004·Current Medicinal Chemistry·Juan TamargoEva Delpón
Dec 21, 2004·Journal of the American College of Cardiology·Denis RoyUNKNOWN CRAFT Investigators
Nov 24, 2005·Journal of Cardiovascular Electrophysiology·David FedidaGregory N Beatch
Mar 28, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Maciej BanachJanusz Zaslonka
Mar 21, 2007·Expert Opinion on Investigational Drugs·David Fedida
Aug 2, 2007·Journal of Cardiovascular Pharmacology·Paul DorianGregory N Beatch
Nov 21, 2007·The Journal of Thoracic and Cardiovascular Surgery·Maciej BanachJan Henryk Goch
Mar 12, 2008·Circulation·Denis RoyUNKNOWN Atrial Arrhythmia Conversion Trial Investigators
Mar 13, 2008·The Annals of Pharmacotherapy·Judy W M Cheng
Oct 22, 2008·The American Journal of Cardiology·Emily ConwayPeter R Kowey
Oct 1, 2008·Circulation·Giovanni MariscalcoAndrea Sala
Oct 3, 2008·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Maciej BanachJacek Rysz
Dec 17, 2008·Current Opinion in Cardiology·Joachim R Ehrlich, Stanley Nattel
Apr 4, 2009·Thyroid Research·Agata Bielecka-DabrowaMaciej Banach
Apr 16, 2009·Current Medical Research and Opinion·Chee W Khoo, Gregory Y H Lip
May 16, 2009·Drugs·Joachim R Ehrlich, Stanley Nattel

❮ Previous
Next ❯

Citations

Jan 19, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Ursula Ravens
Dec 3, 2014·Cardiology Clinics·Muhammad Rizwan SardarPeter R Kowey
Aug 24, 2010·Expert Opinion on Therapeutic Patents·Neil A Castle
Jul 13, 2011·Annals of Medicine·Dariusz KozlowskiMaciej Banach
May 31, 2011·Medicina clínica·Luisa BenitoBlanca Coll-Vinent
Mar 23, 2011·Pharmacology & Therapeutics·Jérôme ThireauSylvain Richard
Jul 14, 2010·Pharmacology & Therapeutics·Ursula Ravens
Mar 13, 2016·Heart Failure Clinics·Muhammad Rizwan SardarPeter R Kowey
Apr 26, 2014·Circulation Research·Christopher E Woods, Jeffrey Olgin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.